Ziextenzo® (pegfilgrastim injection) is a biologic drug (biosimilar) to Neulasta®.
Ziextenzo® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drugs.
Ziextenzo® is the third Sandoz biosimilar available in Canada.
Click here to consult the product monograph of Ziextenzo®
* Ziextenzo® is a registered trademark owned or used under license by Sandoz Canada Inc.
** Neulasta® is a registered trademark of Amgen in Canada.
This site is intended for an audience in Canada